These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 19249626)

  • 1. Tesofensine and weight loss.
    Sommet A; Pathak A; Montastruc JL
    Lancet; 2009 Feb; 373(9665):719; author reply 720. PubMed ID: 19249626
    [No Abstract]   [Full Text] [Related]  

  • 2. [The effect of tesofensine on body weight and body composition in obese subjects--secondary publication].
    Nielsen AL; Larsen TM; Madsbad S; Breum L; Jensen TJ; Kroustrup JP; Astrup A
    Ugeskr Laeger; 2009 Oct; 171(41):2974-7. PubMed ID: 19824222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity.
    Bello NT; Zahner MR
    Curr Opin Investig Drugs; 2009 Oct; 10(10):1105-16. PubMed ID: 19777399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Is there a future for medical treatment of obesity?].
    Richelsen B
    Ugeskr Laeger; 2009 Oct; 171(41):2973. PubMed ID: 19814923
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial.
    Astrup A; Madsbad S; Breum L; Jensen TJ; Kroustrup JP; Larsen TM
    Lancet; 2008 Nov; 372(9653):1906-1913. PubMed ID: 18950853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats.
    Bentzen BH; Grunnet M; Hyveled-Nielsen L; Sundgreen C; Lassen JB; Hansen HH
    Obesity (Silver Spring); 2013 May; 21(5):985-92. PubMed ID: 23784901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is new hope on the horizon for obesity?
    Bray GA
    Lancet; 2008 Nov; 372(9653):1859-1860. PubMed ID: 19041787
    [No Abstract]   [Full Text] [Related]  

  • 8. Tesofensine--a novel potent weight loss medicine. Evaluation of: Astrup A, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1906-13.
    Doggrell SA
    Expert Opin Investig Drugs; 2009 Jul; 18(7):1043-6. PubMed ID: 19548858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of tesofensine on appetite sensations.
    Gilbert JA; Gasteyger C; Raben A; Meier DH; Astrup A; Sjödin A
    Obesity (Silver Spring); 2012 Mar; 20(3):553-61. PubMed ID: 21720440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Under-reporting of adverse effects of tesofensine.
    Astrup A; Madsbad S; Breum L; Jensen TJ; Kroustrup JP; Larsen TM
    Lancet; 2013 Jul; 382(9887):127. PubMed ID: 23849924
    [No Abstract]   [Full Text] [Related]  

  • 11. Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study.
    Rascol O; Poewe W; Lees A; Aristin M; Salin L; Juhel N; Waldhauser L; Schindler T;
    Arch Neurol; 2008 May; 65(5):577-83. PubMed ID: 18474731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat.
    Axel AM; Mikkelsen JD; Hansen HH
    Neuropsychopharmacology; 2010 Jun; 35(7):1464-76. PubMed ID: 20200509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The principle of precaution and the drug treatment of obese subjects].
    C-Soriguer FJ; Tinahones FJ
    Med Clin (Barc); 1999 Apr; 112(13):503-7. PubMed ID: 10353118
    [No Abstract]   [Full Text] [Related]  

  • 14. Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons.
    Perez CI; Luis-Islas J; Lopez A; Diaz X; Molina O; Arroyo B; Moreno MG; Lievana EG; Fonseca E; Castañeda-Hernández G; Gutierrez R
    PLoS One; 2024; 19(4):e0300544. PubMed ID: 38656972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regarding the cardiovascular effects of an herbal ephedra-caffeine weight loss product.
    Rawson ES; Persky AM
    Int J Obes Relat Metab Disord; 2004 Oct; 28(10):1353-4. PubMed ID: 15052276
    [No Abstract]   [Full Text] [Related]  

  • 16. Tesofensine and weight loss.
    Tsai AG
    Lancet; 2009 Feb; 373(9665):719; author reply 720. PubMed ID: 19249625
    [No Abstract]   [Full Text] [Related]  

  • 17. Cardiovascular and psychiatric risk profile and patterns of use in patients starting anti-obesity drugs.
    Willemen MJ; Mantel-Teeuwisse AK; Straus SM; Leufkens HG; Egberts AC; Sturkenboom MC
    Pharmacoepidemiol Drug Saf; 2009 Jul; 18(7):631-8. PubMed ID: 19415767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An acute clinical trial evaluating the cardiovascular effects of an herbal ephedra-caffeine weight loss product in healthy overweight adults.
    Kalman DS
    Int J Obes Relat Metab Disord; 2004 Oct; 28(10):1355-6. PubMed ID: 15365583
    [No Abstract]   [Full Text] [Related]  

  • 19. Is cardiometabolic risk improved by weight-loss drugs?
    Astrup A
    Lancet; 2010 Aug; 376(9741):567-8. PubMed ID: 20673996
    [No Abstract]   [Full Text] [Related]  

  • 20. STRADIVARIUS: a brave trial aimed at clarifying benefits of rimonabant therapy.
    Cardiovasc J Afr; 2008; 19(3):158-9. PubMed ID: 18568179
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.